Healthcare · Biotechnology
Price
$0.57
Market Cap
$3.1M
Employees
5
Beta
0.71
Avg Volume
3,460,382
CEO
Allen Baharaff
Business Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Business History
Price Overview
Last updated: Jun 27, 2026 8:57am (just now)$0.57
+0.00 (+0.00%)
Day Range
$0.55 – $0.57
52-Week Range
$0.41 – $2.34
50-Day MA
$0.62
200-Day MA
$0.88
Volume
25,533.00
Share Structure
Outstanding
5,479,230.00
Float
5,413,835.00
Free Float
98.8%
High free float
— 98.8% of shares trade freely, ~1.2% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (5.4M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.24
Stock Price: $0.57
EPS (Diluted): -2.39
EPS (Diluted): -2.39
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.21
Stock Price: $0.57
Total Equity: $15.78M
Shares: 4,311,323
Total Equity: $15.78M
Shares: 4,311,323
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.08
Market Cap: $3.14M
Total Debt: $0.00
Cash: $3.99M
EBITDA: -$10.31M
Total Debt: $0.00
Cash: $3.99M
EBITDA: -$10.31M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$-749,352
Market Cap: $3.14M
Total Debt: $0.00
Cash: $3.99M
Total Debt: $0.00
Cash: $3.99M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $0.57
Revenue: $0.00
Shares: 4,311,323
Revenue: $0.00
Shares: 4,311,323
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$8.51M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$10.31M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-57.0%
Net Income: -$10.31M
Total Equity: $15.78M
Total Equity: $15.78M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-53.9%
Operating Income: -$8.51M
Tax Rate: 0.0%
Equity: $15.78M
Total Debt: $0.00
Cash: $3.99M
Tax Rate: 0.0%
Equity: $15.78M
Total Debt: $0.00
Cash: $3.99M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
6.55
Current Assets: $18.63M
Current Liabilities: $2.85M
Current Liabilities: $2.85M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $15.78M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $15.78M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 4,311,323
Shares: 4,311,323
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.66
Total Equity: $15.78M
Shares: 4,311,323
Shares: 4,311,323
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.46
Operating CF: -$6.32M
CapEx: $0.00
Shares: 4,311,323
CapEx: $0.00
Shares: 4,311,323
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.57
Stock Price: $0.57
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$10.31M
Net Income: -$10.31M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares GLMD against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 1:39am (7h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $32.9M | $17.7M | $7.5M | $6.3M | $8.5M |
| Operating Income | -$32.9M | -$17.7M | -$7.5M | -$6.3M | -$8.5M |
| Net Income | -$32.5M | -$17.9M | -$6.9M | -$7.5M | -$10.3M |
| EBITDA | -$32.4M | -$17.6M | -$6.9M | -$7.4M | -$10.3M |
| EPS | $-19.48 | $-11.08 | $-30.05 | $-8.08 | $-2.39 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 1:39am (7h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.9M | $2.0M | $2.9M | $4.7M | $4.0M |
| Total Current Assets | $36.1M | $14.7M | $13.2M | $16.1M | $18.6M |
| Total Assets | $36.6M | $16.6M | $16.6M | $18.5M | $18.6M |
| Current Liabilities | $5.9M | $3.1M | $2.8M | $2.2M | $2.8M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.1M | $3.1M | $2.8M | $2.2M | $2.8M |
| Total Equity | $30.5M | $13.4M | $13.9M | $16.3M | $15.8M |
| Retained Earnings | -$168.2M | -$186.0M | -$193.0M | -$200.5M | -$210.8M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 1:39am (7h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$32.9M | -$18.5M | -$6.1M | -$5.9M | -$6.3M |
| Capital Expenditure | $-11,000 | $-4,000 | $0 | $0 | $0 |
| Free Cash Flow | -$32.9M | -$18.5M | -$6.1M | -$5.9M | -$6.3M |
| Acquisitions (net) | $0 | $-17,567 | -$1.5M | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$4.1M | $-868,000 | $848,000 | $1.8M | $-664,000 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 1:39am (7h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$5.8M $5.8M – $5.8M
|
$5.0M $5.0M – $5.0M
|
$17.5M $17.5M – $17.5M
|
$0 |
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$3.9M -$3.9M – -$3.9M
|
-$3.3M -$3.3M – -$3.3M
|
-$7.8M -$7.8M – -$7.8M
|
-$7.6M -$7.6M – -$7.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 1:39am (7h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +46.3% | +57.6% | +16.2% | -35.6% |
| Net Income Growth | +45.0% | +61.3% | -8.8% | -37.1% |
| EBITDA Growth | +45.6% | +61.0% | -8.0% | -39.0% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for GLMD — it's generated by the pipeline (
market-narrative step).
No community reviews yet for GLMD.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30